Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 1
Submit an article Journal homepage
409
Views
14
CrossRef citations to date
0
Altmetric
Infectious disease

Cost–utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan

Ataru IgarashiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan;
,
Wentao TangGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan;
,
Sandrine CureMapi, Uxbridge, UK;
,
Ines GuerraMapi, Uxbridge, UK; Correspondence[email protected]
,
Lucile MariéMapi, Uxbridge, UK;
,
Michael LoprestiJunicon Japan Inc., Tokyo, Japan
&
Kiichiro TsutaniGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan;
show all
Pages 1-10 | Received 31 Mar 2016, Accepted 07 Jul 2016, Published online: 08 Sep 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Bin Wu, Zhenhua Wang & Qing Xie. (2019) Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C. Current Medical Research and Opinion 35:5, pages 847-857.
Read now
Antoine Abou Rached, Selim Abou Kheir, Jowana Saba, Salwa Assaf, Georges Kassis, Yuri Sanchez Gonzalez & Olivier Ethgen. (2018) Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment. Hepatic Medicine: Evidence and Research 10, pages 73-85.
Read now

Articles from other publishers (12)

Hye-Lin Kim, Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Moran Ki, Hwa Young Choi & Sook-Hyang Jeong. (2022) A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective. Clinical and Molecular Hepatology 28:1, pages 91-104.
Crossref
Riichiro Suenaga, Machi Suka, Tomohiro Hirao, Isao Hidaka, Isao Sakaida & Haku Ishida. (2021) Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLOS ONE 16:4, pages e0248748.
Crossref
Xia Wei, Jingyu Zhao & Li Yang. (2020) Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. BMJ Global Health 5:11, pages e003194.
Crossref
Kota Nagai, Kazuki Ide, Yohei Kawasaki, Sachiko Tanaka‐Mizuno, Kahori Seto, Shinji Iwane, Yuichiro Eguchi & Koji Kawakami. (2020) Estimating the cost‐effectiveness of screening for hepatitis C virus infection in Japan. Hepatology Research 50:5, pages 542-556.
Crossref
Yueran Zhuo, Tomoyuki Hayashi, Qiushi Chen, Rakesh Aggarwal, Yvan Hutin & Jagpreet Chhatwal. (2020) Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. Scientific Reports 10:1.
Crossref
Ataru Igarashi, Norihiro Furusyo, Eiichi Ogawa, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara & Jun Hayashi. (2019) Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open 9:6, pages e023405.
Crossref
László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Wankyo Chung, Kyung‐Ah Kim, Eun Sun Jang, Moran Ki, Hwa Young Choi & Sook‐Hyang Jeong. (2018) Cost‐effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea. Journal of Gastroenterology and Hepatology 34:4, pages 776-783.
Crossref
Kyung-Ah Kim, Wankyo Chung, Hwa Young Choi, Moran Ki, Eun Sun Jang & Sook-Hyang Jeong. (2019) Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population. Liver International 39:1, pages 60-69.
Crossref
Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert. (2018) Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy & Practice 3:1, pages 238146831877663.
Crossref
Maria Stepanova & Zobair M. Younossi. (2017) Economic Burden of Hepatitis C Infection. Clinics in Liver Disease 21:3, pages 579-594.
Crossref
Zobair M. Younossi, Atsushi Tanaka, Yuichiro Eguchi, Young-Suk Lim, Ming-Lung Yu, Norifumi Kawada, Yock Young Dan, Craig Brooks-Rooney, Francesco Negro & Mario U. Mondelli. (2017) The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver International 37:2, pages 159-172.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.